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Abstract
Background: Signal transducer and activator of transcription 3 (Stat3) is a member of the Janus-activated kinase(Jak)/
Stat signaling pathway. Abnormal activation of Stat3 plays a critical role in metastasis and invasion in varieties of human 
tumors including pancreatic cancer. This study aimed to investigate the mechanisms of activation and blocking of the 
Stat3 signaling pathway and its effects on invasion and metastasis of human pancreatic cancer cells.
Methods: The Jak inhibitor AG490 and interleukin-6 (IL-6) were added to the culture media of human pancreatic 
cancer cells SW1990 and Capan-2, respectively. Cell growth was measured by MTT assays. Western blotting and 
immunocytochemistry were performed to detect phosphorylated Stat3 (p-Stat3) protein, while VEGF and MMP-2 
mRNA and protein expression were examined with fluorescence quantitative polymerase chain reaction and Western 
blotting, respectively. The invasion ability of SW1990 and Capan-2 cells was determined by cell invasion assay.
Results: Stat3 was activated by IL-6 in Capan-2 cells; protein expression of p-Stat3 was increased significantly in Capan-
2 cells. IL-6 remarkably promoted the growth of Capan-2 cells (P < 0.05), and VEGF and MMP-2 mRNA and protein 
expression were increased significantly. Also, IL-6 increased the invasion ability of Capan-2 cells. AG490 inhibited Stat3 
activation in SW1990 cells. Western blotting and immunocytochemistry analysis showed that p-Stat3 protein 
expression was decreased significantly with AG490 treatment in SW1990 cells. AG490 remarkably inhibited the growth 
of Capan-2 cells (P < 0.05), and VEGF and MMP-2 mRNA and protein expression was decreased significantly. And AG490 
decreased the invasion ability of SW1990 cells.
Conclusions: Abnormal activation of Stat3 plays an important role in the invasion and metastasis of pancreatic cancer. 
Activation and blocking of the Stat3 signaling pathway can affect invasion ability and expression of the VEGF and MMP-
2 genes in pancreatic cancer cells. The Stat3 signaling pathway may provide a novel therapeutic target for treatment of 
pancreatic cancer.
Introduction
Pancreatic cancer is one of the most virulent malig-
nances, with an overall 5-year survival rate of only 3-5%
and a median survival time after diagnosis of less than 6
months[1]. This highly lethal disease is usually diagnosed
in an advanced stage, when there are few or no effective
therapies[2]. Even among patients undergoing a poten-
tially curative resection, the long-term outcome remains
unsatisfactory because of early recurrence and metastatic
disease[3].
Despite the immensity of the clinical problem, the biol-
ogy of pancreatic cancer remains only poorly understood.
Signal transducer and activator of transcription (Stat)
proteins were initially described in the context of regulat-
ing physiological cell signaling. An increasing number of
studies have implicated Stat protein activation, particu-
larly Stat3, in transformation and tumor progression[4].
Activated Stat3 has been shown to promote cell prolifera-
tion, metastasis, and angiogenesis, as well as protect
tumor cells from apoptosis by regulating associated
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Page 2 of 8genes, such as Bcl-xL, Mcl-1, Bcl-2, Fas, cyclin D1, sur-
vivin, c-Myc, VEGF, MMP-2, and MMP-9[5-7].
Recently, accumulating evidence has indicated that
abnormalities in the Stat3 pathway are involved in the
oncogenesis of several cancers. For example, Scholz [8]
and coworkers reported that activation of the Stat3 sig-
naling pathway plays an important role in the progression
of pancreatic cancer, and constitutive activation of Stat3
correlates with cell proliferation in stomach adenocarci-
noma[9], prostate cancer[10], breast carcinoma[11], and
non-small cell lung cancer[12] and also inhibits apopto-
sis[13,14]. Conversely, inhibition of the Stat pathway sup-
presses cancer cell growth and invasion and induces
apoptosis in various cancers[8,11,15,16].
Jak is responsible for the tyrosine phosphorylation of
Stat3 in response to extracellular signals and oncogenes.
The newly described Jak inhibitor AG490 blocks the con-
stitutive activation of Stat3[17]. AG490 was used to selec-
tively block the Jak/Stat3 signaling pathway and inhibit
activation of Stat3 in colorectal cancer cells[18].
The pleiotropic cytokine interleukin-6 (IL-6) is a major
activator of Stat3; IL-6 stimulates the formation of
tyrosine-phosphorylated Stat3 (p-Stat3) in cancer
cells[19,20]. Through the Jak/Stat3 signaling pathway, IL-
6 plays an important role in cell proliferation, apoptosis,
metastasis, and other biological activities [21].
In the present study, we used AG490 to deplete Stat3
protein in the human pancreatic cancer cell line SW1990
and IL-6 to activate Stat3 protein in the human pancre-
atic cancer cell line Capan-2; we then investigated the
changes in cell proliferation and invasion. We also exam-
ined the expression of Stat3 and its active phosphorylated
form in human pancreatic cancer cell lines. In addition,
we evaluated the changes in matrix metalloproteinase 2
(MMP-2) and vascular endothelial growth factor (VEGF)
mRNA and protein expression. Our aim was to demon-
strate that the Stat3 signaling pathway may be critical for
the invasive behavior of pancreatic tumors. Inhibition of




The human pancreatic cancer cell lines SW1990 and
Capan-2 were obtained from the American Type Culture
Collection. Tumor cells were maintained in Dulbecco's
modified Eagle's medium (DMEM), supplemented with
10% fetal calf serum, 100 units/ml penicillin and 100 μg/
mL streptomycin, in a humidified incubator with an
atmosphere of 5% CO2 and 95% air at 37°C. AG490
(Sigma, St Louis, MO, USA) was dissolved in ethanol, 5
mg/ml, and then diluted with the culture medium for
experiments. SW1990 cells were treated with 20 μM
AG490 for 24 hours. Recombinant IL-6 (Peprotech,
Princeton, NJ, USA) was dissolved in 5-10 mmol/L acetic
acid to a concentration of 0.1-0.5 mg/ml and then diluted
with the culture medium for experiments. Capan-2 cells
were treated with 100 ng/mL IL-6 for 24 hours.
MTT assay
Cell viability was determined by 3-(4,5-dimethylthiazole-
2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay.
Pancreatic cancer cells were seeded in 96-well culture
plates in culture medium. After 24 hours, the medium
was changed to fresh culture medium containing either
20 μM/L AG490 or 100 ng/ml IL-6. MTT assays were
performed 24, 48, and 72 hours after AG490 and IL-6
treatment. At the time of the assay, the cells were stained
with 20 μL MTT (5 mg/ml) (Sigma, St Louis, MO, USA)
at 37°C for 4 hours and subsequently made soluble in 150
μL of DMSO. Absorbance was measured at 490 nm using
a microtiter plate reader (Wako, Osaka, Japan). The
results were used to obtain cell growth curves.
Quantification by real-time PCR
Total RNA was isolated using TRIzol LS (Invitrogen,
Carlsbad, CA, USA). The concentration and purity of
RNA was determined using a spectrophotometer. cDNA
was synthesized with M-MLV reverse transcriptase (Pro-
mega, Madison, WI, USA). Quantitative real-time poly-
merase chain reaction (RT-PCR) assays were carried out
using SYBR Green Real-Time PCR Master Mix (Toyobo,
Osaka, Japan) and realplex S RT-PCR amplification
equipment (Eppendorf, Hamburg, Germany).
The primers and amplicon sizes were as follows: MMP-
2 sense strand 5'-TAG CAT GTC CCT ACC GAG TCT-
3', antisense strand 5'- ATT GGA TGG CAG TAG CTG
C-3', with a product length of 151 bp; VEGF sense strand
5'-CTG TCT TGG GTG CAT TGG A-3', antisense strand
5'-ATT GGA TGG CAG TAG CTG C-3', with a product
length of 152 bp; β-actin sense strand 5'-CAC CAA CTG
GGA CGA CAT-3', antisense strand 5'-ATC TGG GTC
ATC TTC TCG C-3', with a product length of 138 bp
(Shenggong Biotech, Shanghai, China).
PCR parameters were as follows: 95°C for 5 minutes,
then 95°C for 30 seconds, 56°C for 30 seconds, 72°C for
40 seconds for 40 cycles. A standard calibration curve for
expression of each mRNA was generated using 8-fold
dilutions of a control RNA sample. MMP-2 and VEGF
mRNA expression was calculated as a ratio to that of β-
actin.
Immunocytochemistry
SW1990 cells and Capan-2 cells were grown on poly-L-
lysine-coated slides in a 6-well plate; after treatment with
AG490 and IL-6, respectively, the slides of 4 groups were
washed twice with PBS and fixed in 4% paraformaldehyde
for 30 minutes at room temperature. Immunostaining
was performed using the streptavidin-biotin complex
Huang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:51
http://www.jeccr.com/content/29/1/51
Page 3 of 8method with the UltraSensitive S-P Kit (Fuzhou Maxim
Biotech, Fuzhou, China). The slides were pretreated first
with 0.3% hydrogen peroxide in PBS for 10 minutes to
inactivate endogenous peroxidase, and then microwave
antigen retrieval was performed with 0.01 mol/L citrate
buffer at pH 6.0 for 20 minutes, followed by incubation
with rabbit anti-human Phospho-Tyr705-Stat3 polyclonal
antibody (1:100, Cell Signaling Technology, Danvers,
MA, USA) at 4°C overnight.
For negative controls, slides were processed as above
but treated with PBS, instead of the primary antibody/
biotinylated secondary antibody, for 30 minutes and per-
oxidase-labeled streptavidin for 30 minutes. Color reac-
tion was developed with 3, 3'-diaminobenzidine as a
chromogen.
Finally, the slides were counterstained with hematoxy-
lin, dehydrated through graded alcohol, and observed
under the microscope. We used the Image Analysis Sys-
tem for protein analysis; 5 different views were selected
for each slide (400 times). Integrated optical density was
used as the measurement of staining strength.
Western blotting
Whole-cell protein extracts and nuclear protein extracts
from pancreatic cancer cells were prepared with RIPA
Lysis Buffer (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and Nuclear Extract Kit (Active Motif, Carlsbad,
CA, USA), respectively, according to the manufacturers'
instructions. Protein concentrations were determined
using an assay kit (Bio-Rad, Hercules, CA, USA).
Lysates containing 100 μg of protein were mixed with
loading buffer with 5% β-mercaptoethanol and heated for
5 minutes at 100°C. Samples were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred onto nitrocellulose membranes by semi-dry
blotting.
Membranes were incubated in blocking buffer (tris-
buffered saline [TBS], 0.1% Tween 20, and 5% non-fat dry
milk) for 1 hour at room temperature, followed by
hybridization with anti-p-Stat3 (tyr-705) antibody (Cell
Signaling Technology, 1:1000 dilution), anti-Stat3 anti-
body (Cell Signaling Technology, 1:1000 dilution), anti-
MMP-2 antibody (Santa Cruz Biotechnology, 1:500 dilu-
tion), anti-VEGF antibody (Santa Cruz Biotechnology,
1:500 dilution) or anti β-actin antibody (Lab Vision, Fre-
mont, CA, USA, 1:100 dilution) at 4°C overnight.
After 3 washes in TBS/0.1% Tween 20, the membranes
underwent hybridization with a horseradish peroxidase-
conjugated secondary antibody rabbit IgG (Santa Cruz
Biotechnology, 1:5000 dilution) for 1 hour at room tem-
perature. After 3 washes in TBS/0.1% Tween 20, signals
were detected by chemiluminescence using western blot-
ting luminol reagent (Santa Cruz Biotechnology).
Invasion assay
The invasion assay was performed using a specialized
invasion chamber (Chemicon, Temecula, CA, USA). The
inserts contained an 8-μm pore size polycarbonate mem-
brane with a precoated thin layer of basement membrane
matrix (ECMatrix). Briefly, media supplemented with
10% fetal bovine serum was poured into the lower cham-
ber as a hemo-attractant. After reaching 60-70% subcon-
fluence, pancreatic cancer cells were trypsinized and
resuspended in DMEM (1×106 cells/ml), and 0.3 ml was
re-seeded into the upper chambers. Cells were cultured
in medium containing either vehicle alone (control) or
indicated doses of AG490.
After 24 hours of incubation at 37°C, non-invasive cells
were removed from the upper surface of the membrane
using a moist cotton-tipped swab. Invasive cells on the
lower surface of the membrane, which had invaded the
ECMatrix and had migrated through the polycarbonate
membrane, were stained with the staining solution for 20
minutes and rinsed with distilled water several times.
Invasiveness was quantitated by selecting 10 different
views (400 times) and counting the number of invasion
cells.
Statistical analysis
All assays were conducted 3 times and found to be repro-
ducible. Data were expressed as mean ± SD. Statistical
correlation of data between groups was checked for sig-
nificance by Student's t test. Differences with P < 0.05
were considered significant. These analyses were per-
formed using SPSS 11.0 software.
Results
Effects of AG490 and IL-6 on growth in pancreatic cancer 
cells
Because Stat3 activation was positively associated with
proliferation potential in cancer cells, we measured the
absorbance of the SW1990 cell line in the presence of
AG490. Incubation with 20 μM/L AG490 for 72 hours
markedly reduced proliferation of SW1990 cells (P <
0.05), but incubation with 20 μM/L AG490 for 24 and 48
hours did not reduce proliferation of SW1990 cells (P >
0.05). We measured the absorbance of the Capan-2 cell
line in the presence of IL-6, a cytokine that can active the
Jak/Stat3 signaling pathway. Incubation with 100 ng/ml
IL-6 for 48 and 72 hours increased proliferation of
Capan-2 cells significantly (P < 0.05) , but incubation with
100 ng/ml IL-6 for for 24 hours did not increase prolifera-
tion of SW1990 cells (P > 0.05).
Because of these results, cell invasion assay was per-
formed with doses of 20 μM/L AG490 for 24 hours and
100 ng/ml IL-6 for for 24 hours to ignore the influence of
cell viability. The growth curve was obtained according to
the absorbance of the cells. (Figure 1)
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expression in pancreatic cancer cells
The mRNA levels of the VEGF and MMP-2 genes in
SW1990 and Capan-2 cells were examined by RT-PCR.
RNA samples were extracted from SW1990 cells treated
for 24 hours with 20 μM AG490 and then subjected to
RT-PCR for MMP-2, VEGF and β-actin. AG490 signifi-
cantly decreased the expression of MMP-2 and VEGF
mRNAs in SW1990 cells. Treatment with 100 ng/ml IL-6
in Capan-2 cells for 24 hours markedly increased the
VEGF and MMP-2 mRNA levels. Data are presented as
mean ± SD. (Figure 2)
Effects of AG490 and IL-6 on p-Stat3 protein expression in 
pancreatic cancer cells
Immunocytochemical staining showed that p-Stat3 was
mainly expressed in the nucleus and weakly expressed in
the cytoplasm of SW1990 and Capan-2 cells. Treatment
with 20 μM/L AG490 in SW1990 cells for 24 hours mark-
edly decreased the intensity of p-Stat3 expression. Treat-
ment with 100 ng/ml IL-6 in Capan-2 cells for 24 hours
significantly increased the intensity of p-Stat3 expression.
(Figure 3)
Effects of AG490 and IL-6 on p-Stat3, VEGF and MMP-2 
protein levels in pancreatic cancer cells
We used western blotting to examine the effects of
AG490 and IL-6 on p-Stat3, VEGF, and MMP-2 protein
levels of SW1990 and Capan-2 cells. AG490 did not affect
total Stat3 protein levels in SW1990 cells after treatment
with 20 μM/L AG490 for 24 hours but did suppress p-
Stat3, VEGF, and MMP-2 protein levels. Treatment of
Capan-2 cells with 100 ng/ml IL-6 for 24 hours increased
p-Stat3, VEGF, and MMP-2 protein expression levels sig-
nificantly. (Figure 4)
Effects of AG490 and IL-6 on invasive ability of pancreatic 
cancer cells
To evaluate the effects of regulation of Stat3 activity on
pancreatic cancer invasion, we performed an in vitro
invasion assay using AG490 and IL-6 (Figure 5). Accord-
ing to the number of invasive cells, AG490 markedly
reduced invasion of SW1990 cells (P < 0.05) compared
with the vehicle-treated cells. IL-6 increased the invasion
ability of Capan-2 cells significantly (P < 0.05). (Figure 5)
Discussion
The Jak/Stat3 signaling pathway plays a vital role in regu-
lating a number of pathways in tumorigenesis, including
cell cycle progression, apoptosis, tumor angiogenesis, and
tumor cell evasion of the immune system. Cytokines and
growth factors bind to the membrane receptors that acti-
vate the nonreceptor tyrosine kinase. Once the tyrosine is
phosphorylated, two Stat3 monomers form dimers
through reciprocal phosphotyrosine-SH2 interactions,
translocate to the nucleus, where they bind to Stat3-spe-
cific DNA-response elements of target genes, and induce
gene transcription[22].
During malignant transformation, Stat3 frequently is
overexpressed and constitutively activated by tyrosine
phosphorylation. Previous studies have demonstrated
that activated Stat3 is overexpressed in human pancreatic
cancer tissues and cell lines[23].
Despite the clear importance of Stat3 in cell prolifera-
tion, invasion, metastasis, and survival in human pancre-
Figure 2 VEGF and MMP-2 mRNA levels in SW1990 and Capan-2 
cells were detected by real time PCR. The extracted total RNA was 
reverse-transcribed into single-stranded cDNA, and real-time PCR was 
performed. Interleukin-6 (IL-6) markedly increased MMP-2 and VEGF 
mRNA expression in Capan-2 cells(P = 0.000, P = 0.000). AG490 signifi-
cantly decreased MMP-2 and VEGF mRNA expression in SW1990 cells(P 
= 0.008, P = 0.000). β-actin was used as an endogenous control. * P < 
0.01, versus Capan-2 cell group; #P < 0.01, versus SW1990 cell group.
Figure 1 Pancreatic cancer cell growth was detected by MTT as-
say. SW1990 and Capan-2 cells growing in 96-well plates were treated 
with AG490 and interleukin-6 (IL-6), respectively, for 24, 48 and 72 
hours. Incubation with 20 μM/L AG490 for 72 hours markedly reduced 
proliferation of SW1990 cells (P = 0.000), but incubation with 20 μM/L 
AG490 for 24, 48 hours did not reduce proliferation of SW1990 cells (P 
= 0.051, P = 0.060). Incubation with 100 ng/ml IL-6 for 48 and 72 hours 
increased proliferation of Capan-2 cells significantly (P = 0.001, P = 
0.000) , but incubation with 100 ng/ml IL-6 for for 24 hours did not in-
crease proliferation of SW1990 cells (P = 0.073). Data are mean ± SD of 
8 wells. A = Absorbance.
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Figure 3 p-Stat3 protein expression was detected by immunocytochemistry. Immunocytochemical staining showed that p-Stat3 was mainly 
expressed in the nucleus and weakly expressed in the cytoplasm of SW990 cells and Capan-2 cells. Expression of p-Stat3 protein in Capan-2 cells (A) 
and SW1990 cells (C). After treatment with interleukin-6 (IL-6) for 24 hours on Capan-2 cells (B), we observed that the intensity of p-Stat3 expression 
increased(P = 0.012). After treatment with AG490 for 24 hours on SW1990 cells (D), we observed that the intensity of p-Stat3 expression decreased (P 
= 0.006) (original magnification, ×400). (E) Integrated optical density of every group. Bars indicate mean ± SD. * P < 0.01, versus Capan-2 cell group; # 
P < 0.01, versus SW1990 cell group.
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pancreatic cancer invasion and metastasis has not been
fully characterized. In our previous studies, we compared
the levels of p-Stat3 protein and the invasion ability
between SW1990 and CaPan-2 cell lines. We found that
p-Stat3 protein levels were significantly higher in
SW1990 cells compared to the CaPan-2 cells. Further-
more, invasion assay in vitro indicated significant inva-
sion ability of SW-1990 cells, while weak invasion ability
was observed in CaPan-2 cells[24]. In the present study,
we used immunocytochemistry and Western blotting to
detect the level of p-Stat3 protein in SW1990 and Capan-
2 cells after theatment with AG490 or IL-6. We found
that the p-Stat3 protein level was significantly decreased
in SW1990 cells after treatment with AG490 and mark-
edly increased in Capan-2 cells after treatment with IL-6.
These results demonstrate that AG490 strongly sup-
presses Stat3 activity and that IL-6 promotes Stat3 activ-
ity in pancreatic cancer cell lines.
Stat3 is an oncogene that is constitutively active in
many tumor types and promotes cell proliferation and
survival[21,25]. Inappropriate and constitutive activation
of Stat3 may be responsible for pancreatic cancer pro-
gression by regulating the expression of target genes,
such as c-Myc, Bcl-xL, p21WAF1, and cyclinD1, and
functional inactivation of Stat3 by dominant-negative
Stat3 or AG490 could inhibit the proliferation and pro-
mote the apoptosis of pancreatic cancer cells[8,26].
Moreover, evidence indicates that constitutive activa-
tion of Stat3 influences invasion and metastasis. For
example, activation of Stat3 in thymic epithelial
tumors[27], colorectal adenocarcinoma[28], and cutane-
ous squamous cell carcinoma[29] correlates with invasion
and lymph node metastasis.
In our study, we examined the effects of AG490 and IL-
6 on growth capability of pancreatic cancer cells. The
MTT assay indicated that IL-6 can stimulate the growth
of Capan-2 cells, and proliferation of SW1990 cells was
attenuated when cells were treated with AG490. We
examined the invasive ability of these cells using a cell
invasion assay kit. We found that SW1990 cells showed a
weaker level of invasion after treatment with AG490. In
contrast, Capan-2 cell invasion was significantly
increased by IL-6. Therefore, there is a strong relation-
Figure 4 Stat3, p-Stat3, MMP-2 and VEGF protein expression in 
SW1990 and Capan-2 cells were detected by Western blotting. 
Protein samples extracted from SW1990 and Capan-2 cells treated for 
24 hours with AG490 and interleukin-6 (IL-6), respectively, were sub-
jected to western blotting for Stat3, p-Stat3, MMP-2, VEGF and β-actin 
proteins. AG490 and IL-6 did not affect total Stat3 protein levels. AG490 
decreased p-Stat3, MMP-2 and VEGF protein expression in SW1990 
cells(P = 0.010, P = 0.000, P = 0.009). IL-6 markedly increased p-Stat3, 
MMP-2 and VEGF protein expression in Capan-2 cells(P = 0.000, P = 
0.011, P = 0.005). The levels of β-actin expression were determined as a 
control for equivalent protein loading.
Figure 5 The invasion assay was performed using a specialized 
invasion chamber. The invasion chamber included a 24-well tissue-
culture plate with 12 cell-culture inserts. The blue-stained cells are 
those that invaded the basement membrane matrix (ECMatrix) and mi-
grated through the polycarbonate membrane to the lower surface of 
the membrane. The invasion assay indicated that interleukin-6 (IL-6) 
significantly increased the invasion ability of Capan-2 cells (A, B) (P = 
0.004), and AG490 markedly reduced invasion of SW1990 cells (C, D) (P 
= 0.010) (original magnification ×200). (E) Effects of AG490 and IL-6 on 
invasion ability of pancreatic cancer cells. Bars indicate mean ± SD. * P 
< 0.05, versus Capan-2 cell group; #P < 0.01, versus SW1990 cell group.
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human pancreatic cancer cells.
Tumor invasion and metastasis depend on angiogene-
sis, which is the formation of new blood vessels from a
pre-existing network of capillaries. VEGF is known to be
a potent angiogenic mitogen that plays an important role
in tumor angiogenesis, invasion, and metastasis[30]. The
role of Stat3 in angiogenesis was first shown when VEGF
was found to be a direct target of Stat3 in mouse mela-
noma cells[6] and then confirmed by a study in a human
pancreatic cancer system[31].
A recent study has reported that constitutively acti-
vated Stat3 directly activated the VEGF promoter,
whereas dominant-negative Stat3 inhibited the VEGF
promoter. Furthermor, a Stat3-responsive element on the
VEGF promoter was identified using a protein-DNA
binding assay and confirmed using a promoter mutagene-
sis assay[31]. Our previous study also found that silencing
of the Stat3 gene by RNAi decreases VEGF expression in
the pancreatic cancer cell line SW199023[23]. In the pres-
ent study, we also found that AG490 significantly
decreased the mRNA and protein expression of VEGF in
SW1990 cells, and IL-6 markedly increased the VEGF
mRNA and protein expression in Capan-2 cells.
According to studies that have used clinical samples of
pancreatic cancer and pancreatic cancer cell lines, MMPs
play important roles in tumor cell invasion and metasta-
sis by degrading components of the basement mem-
branes and extracellular matrix[32,33]. Specifically,
activated Stat3 regulates tumor invasion of melanoma
cells by regulating the gene transcription of MMP-2. Fur-
thermore, a high-affinity Stat3-binding element is identi-
fied in the MMP-2 promoter and Stat3 could upregulate
the transcription of MMP-2 through direct interaction
with the MMP-2 promoter[7,34]. In our present study,
the use of AG490 markedly reduced MMP-2 mRNA and
protein expression in SW1990 cells, and IL-6 significantly
increased MMP-2 mRNA and protein expression in
Capan-2 cells through activation of the Stat3 signaling
pathway.
Collectively, our findings strongly suggest that the Jak/
Stat3 pathway plays a significant role in pancreatic cancer
cell invasion. Targeting of Stat3 activation may prove to
be a more effective approach to controlling invasion than
merely targeting individual molecules, such as VEGF and
MMP-2, possibly representing a novel approach to regu-
lating pancreatic cancer invasion.
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